Streetbeat News

Price Targets

RDDT

Raymond James analyst Josh Beck has maintained a Strong Buy rating on Reddit (NYSE:RDDT) and increased the price target from $70 to $80.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:52 pm

META

Raymond James analyst Josh Beck maintains a Strong Buy rating on Meta Platforms and raises the price target from $600 to $650.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:51 pm

CVS

EAT

LC

LHX

NKE

Several top Wall Street analysts have upgraded their ratings for major companies, including L3Harris Technologies, LendingClub, NIKE, Brinker International, and CVS Health. These upgrades reflect positive outlooks and increased price targets for these stocks.

Portfolio Pulse from Avi Kapoor

October 10, 2024 | 12:49 pm

BMRC

DA Davidson analyst Jeff Rulis has upgraded Bank of Marin (NASDAQ:BMRC) from Neutral to Buy, setting a price target of $24.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:48 pm

APLD

Craig-Hallum analyst George Sutton has maintained a Buy rating on Applied Digital (NASDAQ:APLD) and increased the price target from $10 to $12.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:47 pm

INVH

Mizuho analyst Haendel St. Juste maintains a Neutral rating on Invitation Homes (NYSE:INVH) and lowers the price target from $36 to $35.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:41 pm

AMH

Mizuho analyst Haendel St. Juste maintains an Outperform rating on American Homes 4 Rent (NYSE:AMH) and raises the price target from $39 to $40.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:40 pm

ALTM

Mizuho analyst John Roberts maintains a Neutral rating on Arcadium Lithium (NYSE:ALTM) but raises the price target from $4.3 to $5.85.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:39 pm

LXU

UBS analyst Joshua Spector has upgraded LSB Industries (NYSE:LXU) from Neutral to Buy and increased the price target from $9.5 to $11.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:38 pm

HRMY

Mizuho analyst Graig Suvannavejh maintains an Outperform rating on Harmony Biosciences and raises the price target from $42 to $52.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:37 pm